Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia

Southern Medical Journal

Volumn 102, Issue 4, 2009, Pages 361-368

  Takebayashi, Kohzo ^a   Suetsugu, Mariko ^a   Matsumoto, Sachiko ^a   Aso, Yoshimasa ^a   Inukai, Toshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Adipokine; Colestimide; MCP 1; Oxidative stress; Rosuvastatin

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; COLESTILAN; GLIBENCLAMIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NATEGLINIDE; PIOGLITAZONE; RETINOL BINDING PROTEIN 4; ROSUVASTATIN; SULFONYLUREA;

ADULT; ARTICLE; BLOOD EXAMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIET THERAPY; DRUG EFFECT; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

C-REACTIVE PROTEIN; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DINOPROST; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPICHLOROHYDRIN; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMIDAZOLES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PYRIMIDINES; RESINS, SYNTHETIC; RETINOL-BINDING PROTEINS; SULFONAMIDES;

EID: 67651174458     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31819bd023     Document Type: Article

References (35)

1. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized trial and cohort study. Lancet 2004; 364:685-696.
2. Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004;26:1368-1387.
3. Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators. Effect of very high-insensitivity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565.
4. Ortego M, Bustos C, Hernández-Presa MA, et al. Atorvastatin reduces NFκB activation and chemokine expression in vascular smooth muscle cells. Atherosclerosis 1999;147:253-261. (Pubitemid 29512257)
5. Jialal I, Stein D, Balis D, Grundy SM, et al. Effect of hydroxymethyl glutaryl coenxyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935. (Pubitemid 32322218)
6. Hussein O, Schlezinger S, Rosenblat M, et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997;128:11-18. (Pubitemid 27065256)
7. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415-426.
8. Sugiyama S, Fukushima H, Kugiyama K, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007;194:e43-e51. (Pubitemid 47513070)
9. Takagi T, Matsuda M, Abe M, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008; 196:114-121.
10. Chu CH, Lee JK, Lam HC, et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest 2008;31:42-47.
11. Shetty GK, Economides PA, Horton ES, et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-2457.
12. MCI-196 Study Group. Study on the usefulness of MCI-196 in patients with hypercholesterolemia. Rinsho Iyaku 1996;12:1641-1692.
13. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54:53-58. (Pubitemid 46481671)
14. Kawabata Y, Ikegami H, Fujisawa T, et al. Bile acid binding resin ameliorates glycemic control in patients with type 2 diabetes [abstract]. Diabetes 2006;55(suppl 1):A120.
15. Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006;73:277-284. (Pubitemid 44663094)
16. Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007;56:239-247. (Pubitemid 46263124)
17. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-362. (Pubitemid 41065039)
18. Graham TE, Yang Q, Blüher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-2563. (Pubitemid 43882351)
19. Qi Q, Yu Z, Ye X, et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 2007;92:4827-4834. (Pubitemid 350223466)
20. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidative stress in arterothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17:2309-2315. (Pubitemid 28015962)
21. Reilly MP, Praticò D, Delanty N, et al. Increased formation of distinct F2α isoprostanes in hypercholesterolemia. Circulation 1998;98:2822-2828. (Pubitemid 29003962)
22. Wada T, Fruichi K, Sakai N, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000;58:1492-1499. (Pubitemid 30739655)
23. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008;294:F697-F701.
24. Helmersson J, Basu S. F2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids 1999;61:203-205. (Pubitemid 29520811)
25. Takebayashi K, Matsumoto S, Aso Y, et al. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006;91:2214-2217. (Pubitemid 43855008)
26. Japan Diabetes Society. Treatment Guide for Diabetes. Tokyo, Japan, Bunkodo, 2007.
27. Panagiotakos DB, Pitsavos C, Skoumas J, et al. Importance of LDL/ HDL cholesterol ratio as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: a 15-year follow-up (1987-2002). Curr Med Res Opin 2003;19:89-94.
28. Takebayashi K, Aso Y, Inukai T. Role of retinol-binding protein 4 in the pathogenesis of type 2 diabetes. Expert Rev Endocrinol Metab 2008;3:175-185.
29. Takebayashi K, Suetsugu M, Wakabayashi S, et al. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007;92:2712-2719. (Pubitemid 47037380)
30. Corna D, Sangalli F, Cattaneo D, et al. Effect of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. Am J Nephrol 2007;27:630-638. (Pubitemid 350014950)
31. Onishi T, Sano N, Takikawa H. Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum. J Gastroenterol Hepatol 2002;17:697-701. (Pubitemid 34748162)
32. Kajiyama G, Tzazuma S, Yamashita G. Effect of MCI-196 on biliary lipids metabolism in patients with hypercholesterolemia. Rinsho Iyaku 1996;12:1349-1359.
33. Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-1109.
34. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439:484-489. (Pubitemid 43152840)
35. Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 2007;56:2485-2493. (Pubitemid 47523255)